Supernus Pharmaceuticals has been granted a patent for a method of treating neurological disorders like Parkinson’s disease using extended-release amantadine. The patent also covers a solid oral tablet dosage form with specific dimensions and release characteristics. GlobalData’s report on Supernus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Supernus Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Supernus Pharmaceuticals's grant share as of January 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Extended-release amantadine tablet for treating neurological disorders
A recently granted patent (Publication Number: US11833121B2) discloses a solid oral tablet dosage form containing amantadine or its pharmaceutically acceptable salt in both extended release and immediate release forms. The tablet comprises approximately 258 mg of amantadine free base equivalent, with at least 50% of the drug in extended release form. The tablet's dimensions range from 0.2 mL to 0.6 mL in volume, a wall height of 3 mm to 6 mm, and the largest dimension between 8 mm to 15 mm. The dosage form is designed to provide a mean change in amantadine plasma concentration over time that is 40% to 70% of that provided by an equivalent amount of immediate-release amantadine in a single-dose human pharmacokinetic study conducted within 0 to 4 hours post-administration.
Another aspect of the patent covers a solid oral tablet dosage form with approximately 193 mg of amantadine free base equivalent, following similar specifications as the previous claim. The tablet's dimensions range from 0.1 mL to 0.5 mL in volume, a wall height of 3 mm to 6 mm, and the largest dimension between 8 mm to 14 mm. The dosage form aims to provide a mean change in amantadine plasma concentration over time that is 40% to 70% of that provided by an equivalent amount of immediate-release amantadine in a single-dose human pharmacokinetic study conducted within 0 to 4 hours post-administration. Additionally, a specific claim within this patent specifies a tablet volume of about 0.18 mL to 0.42 mL for optimal performance based on the outlined criteria.
To know more about GlobalData’s detailed insights on Supernus Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
